Stay updated with breaking news from Cell Reports. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF), a specialist in macrophage reprogramming and anticancer immunotherapies, has shared its breakthrough...
Is Inflation Licked?; Fed Operating Losses Pile Up; Bank of Canada Holds Steady as Inflation Cools By James Christie Good day. Confident that the Federal Reserve is now cruising to its goal of...
Bexmarilimab monotherapy shows efficacy in achieving disease control and prolonged survival in late-stage metastatic solid tumorsCLEVER-1 targeting is safe and well-tolerated with no serious adverse effectsBexmarilimab induced macrophage activation and increased IFNɣ signaling in patients who achieved disease control and prolonged survival TURKU, Finland and BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical co
<p style="text-align:justify"><strong>The treatment of pancreatic cancer, an aggressive form of cancer associated with high mortality rates, is challenging owing to limited options and anticancer screening models. High mortality has been attributed to the unique tumor microenvironment (TME). Researchers from Japan have created a pancreatic ductal adenocarcinoma (PDAC) organoid model using human-induced pluripotent stem cell (hiPSC) technology, simulating desirable TME properties. Their research findings have far-reaching consequences in the field of cancer biology.</st...
News and events briefs